1126-73-4

Basic information

• Product Name: 2-PROPENAMIDE, 3-(3-PYRIDINYL)-
• Synonyms: 2-PROPENAMIDE, 3-(3-PYRIDINYL)-;RARECHEM AL MA 0109
• CAS NO: 1126-73-4
• Molecular Formula: C8H8N2O
• Molecular Weight: 0
• Mol File: 1126-73-4.mol

Chemical Properties

• Boiling Point: 379.7°C at 760 mmHg
• Flash Point: 183.5°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 5.73E-06mmHg at 25°C
• Refractive Index: 1.621
• CAS DataBase Reference: 2-PROPENAMIDE, 3-(3-PYRIDINYL)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PROPENAMIDE, 3-(3-PYRIDINYL)-(1126-73-4)
• EPA Substance Registry System: 2-PROPENAMIDE, 3-(3-PYRIDINYL)-(1126-73-4)

Safety Data

• Hazardous Substances Data: 1126-73-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Propenamide, 3-(3-pyridinyl)is utilized as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the creation of molecules with specific therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 2-Propenamide, 3-(3-pyridinyl)serves as an intermediate for the synthesis of various agrochemicals. Its role in this field is crucial for the development of effective pesticides and other agricultural chemicals that can protect crops and enhance agricultural productivity.
Used in Neurological Disorder Treatment:
2-Propenamide, 3-(3-pyridinyl)has been studied for its potential use in the treatment of neurological disorders. Its specific chemical structure may allow it to interact with biological targets in the nervous system, offering a new avenue for the development of treatments for conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Used as a Protein Tyrosine Phosphatase 1B Inhibitor:
2-PROPENAMIDE, 3-(3-PYRIDINYL)has also been investigated for its potential as an inhibitor of protein tyrosine phosphatase 1B (PTP1B). Inhibition of PTP1B is considered a promising therapeutic strategy for the management of type 2 diabetes, as it can help regulate insulin signaling and improve glucose homeostasis. By targeting this enzyme, 2-Propenamide, 3-(3-pyridinyl)may contribute to the development of novel diabetes treatments.

InChI:InChI=1/C8H8N2O/c9-8(11)4-3-7-2-1-5-10-6-7/h1-6H,(H2,9,11)

Upstream product

• 78584-30-2 methyl 3-(3-pyridinyl)-2-propynoate 
• 1120-90-7 3-iodopyridine 
• 78597-55-4 3-(pyridin-3-yl)propiolamide 
• 626-55-1 3-Bromopyridine 
• 79-06-1 2-propenamide 
• 54495-51-1 (E)-3-(2-pyridyl)acrylic acid 
• 81124-48-3 methyl (E)-3-(3-pyridyl)acrylate 
• 19337-97-4 trans-3-(3-pyridyl)acrylic acid 

Downstream Products

• 54356-27-3 (E)-3-(pyridin-3-yl)acrylonitrile 

Relevant articles and documents

Organocatalytic Trans Semireduction of Primary and Secondary Propiolamides: Substrate Scope and Mechanistic Studies

We report a chemoselective, phosphine-catalyzed semireduction of primary and secondary propiolamides. In the presence of stoichiometric pinacolborane and catalytic n-tributylphosphine, a variety of propiolamides were successfully converted to the corresponding acrylamides in excellent yield with (E)-stereoselectivity. The reaction condition is tolerant of various functional groups including alkene, alkyne, ketone, or ester. Deuterium labeling studies established that the hydride from activated pinacolborane is added to the α-carbon and the proton on the amide nitrogen is abstracted by the ?-carbon to furnish the (E)-acrylamides. DFT calculations revealed a clear energetic driving force for the (E)- over the (Z)-isomer. (Figure presented.).

Catalytic, transition-metal-free semireduction of propiolamide derivatives: Scope and mechanistic investigation

We report a transition-metal-free trans-selective semireduction of alkynes with pinacolborane and catalytic potassium tert-butoxide. A variety of 3-substituted primary and secondary propiolamides, including an analog of FK866, a potent nicotinamide mononucleotide adenyltransferase (NMNAT) inhibitor, are reduced to the corresponding (E)-3-substituted acrylamide derivatives in up to 99% yield with >99:1 E/Z selectivity. Mechanistic studies suggest that an activated Lewis acid-base complex transfers a hydride to the α-carbon followed by rapid protonation in a trans fashion.

(E)-3-heteroaromatic propyl-2-enoic acid derivative as well as preparation and application thereof

The invention relates to a (E)-3-heteroaromatic propyl-2-enoic acid derivative, and also relates to a preparation method and pharmaceutical application thereof. The compound is a novel Nrf2 activatorand has the effects of resisting oxidative stress, resisting neuritis and enhancing mitochondrial functions and biogenesis by effectively activating an Nrf2 signal path, so that nerve cells are protected, and the compound can be used for treating neurodegenerative diseases and cerebral apoplexy. In addition, the novel Nrf2 activator can also be used to treat autoimmune diseases, diabetes and nephropathy, and other chronic diseases.

Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents

This is the first report of 5-styryl-oxathiazol-2-ones as inhibitors of the Mycobacterium tuberculosis (Mtb) proteasome. As part of the study, the structure-activity relationship of oxathiazolones as Mtb proteasome inhibitors has been investigated. Furthermore, the prepared compounds displayed a good selectivity profile for Mtb compared to the human proteasome. The 5-styryl-oxathiazol-2-one inhibitors identified showed little activity against replicating Mtb, but were rapidly bactericidal against nonreplicating bacteria. (E)-5-(4-Chlorostyryl)-1,3,4-oxathiazol-2-one) was most effective, reducing the colony-forming units (CFU)/mL below the detection limit in only seven days at all concentrations tested. The results suggest that this new class of Mtb proteasome inhibitors has the potential to be further developed into novel antitubercular agents for synergistic combination therapies with existing drugs.

Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2

As part of an effort to identify novel selective modulators of sirtuins, we synthesized and tested several isosteres and constrained analogues of nicotinamide. Biological data suggest that compound 2 is selective for Sirt3 over Sirt1 and Sirt2.